Thursday 28th of October 2021

Follow Us

Breaking News

Russian Health Ministry registers EpiVacCorona-N coronavirus vaccine

 MOSCOW : The Russian Health Ministry has registered the EpiVacCorona-N coronavirus vaccine, as seen from the state register of medicinal products. 

EpiVacCorona-N was developed by the Vector Center of Russian public health and consumer protection watchdog Rospotrebnadzor. 

The vaccine can be used to reduce the risk of contracting the novel coronavirus infection in adults aged from 18 to 60 and shall be administered twice, with each shot 14 days apart, according to the vaccine's manual.

 Among the contraindications to the use of EpiVacCorona-N, the document lists hypersensitivity to its components, allergic responses, acute infectious and non-infectious illnesses, chronic illnesses in an acute phase, primary immunodeficiency, malignant tumors and blood disorders, pregnancy, and lactation. 

The second shot of EpiVacCorona-N shall not be administered if the first one produced an allergic response, it says. 

 

 

 In addition, "due to a lack of information," the vaccine might potentially pose risks to patients with autoimmune diseases and malignant tumors, the manual says. 

As possible adverse effects of the vaccine, the manual mentions pain at the injection site and a brief fever up to 38.5 degrees Celsius. Angioedema is also listed among possible rare adverse effects. 

According to the information available on the register, the vaccine will be manufactured at Vector-BiAlgam, Geropharm, and the Vector Center. 

The Federal Service for Intellectual Property (Rospatent) registered the AURORA-Covid-19 trademark on July 5, to be used as a brand name in marketing the EpiVacCorona-N vaccine. 

EpiVacCorona-N is now the fifth coronavirus vaccine registered in Russia. 

Russia has been conducting a mass vaccination campaign against coronavirus since January 18, using the Sputnik V and Sputnik Light vaccines developed by the Health Ministry's Gamaleya Research Center, EpiVacCorona developed by Rospotrebnadzor, and CoviVac developed by the Russian Academy of Sciences' Chumakov Center.

Related US & Latin America News

First Lady Calls Military Spouse Employment a National Security Imperative

 Washingtn,FASTMAIL - As the Military Spouse Employment Partnership turns 10 years old, First Lady Dr. Jill Biden said military spouse employment is a national security imperative.  Speaking today at the virtual 2021 Annual Official Opening Event and New Partner Induction Ceremony, Biden e....

U.S. Government Still Working to Evacuate Afghans

 Washington,FASTMAIL –US Secretary of Defense Lloyd J. Austin III  said in Brussels "We continue to work to ensure that those people who have helped us have the opportunity to leave the country if they so desire." Kirby told reporters Austin was referring to the larger U.S.....

2 dead, 5 wounded in US mall shooting

 Washington,FASTMAIL -Two people were killed and at least five others wounded, including a police officer, in a shooting Monday at a mall in the US state of Idaho, police said. The incident occurred in the afternoon at the Boise Towne Square Mall in the city of Boise. At a press conference, Boi....

DoD Releases Report on Defense Spending by State in Fiscal Year 2020

 Washington<FASTMAIL -The Department of Defense’s Office of Local Defense Community Cooperation (formerly the Office of Economic Adjustment) released its Fiscal Year 2020 Defense Spending by State report to help states and communities better understand the components of defense spendin....

US Defence Secretary Participates in the NATO Defense Ministerial Meeting

 Washington, FASTMAIL -Secretary of Defense Lloyd J. Austin III participated in his first in-person NATO Defense Ministerial on October 21-22 hosted by NATO Secretary General Jens Stoltenberg.  This visit marked the end of his regional trip, and enabled further discussion on security issue....

Links
Contact
Editor :
Jagadananda Pradhan
Email :
fastmail@yahoo.com
For Ads :
fastmailads@gmail.com
Ph : (+91)6764295999
Contact Us
© 2021 Fast Mail Media Pvt Ltd. All Rights Reserved.
Developed by : FM Media Pvt Ltd.